Skip to main content
      Class V #Lupus Nephritis usually takes longer to treat. Stay the course if no contraindications and taper steroids! - Dr

      TheDaoIndex KDAO2011

      9 months 3 weeks ago
      Class V #Lupus Nephritis usually takes longer to treat. Stay the course if no contraindications and taper steroids! - Dr A Askanase #ACR24 LN Guidelines @RheumNow https://t.co/4BBuAWi2da
      Improving the Value of Musculoskeletal Ultrasound in Rheumatology Care #ACR24

      MSUS has emerged as a powerful asset in r

      Dr. John Cush RheumNow

      9 months 3 weeks ago
      Improving the Value of Musculoskeletal Ultrasound in Rheumatology Care #ACR24 MSUS has emerged as a powerful asset in rheumatology, providing a real-time, non-invasive, and cost-effective solution for diagnosing and managing inflammatory arthritis conditions such as RA and PsA.… https://t.co/iH9IZmHhSz https://t.co/am5LoBCdpe
      RheumNow’s expanded coverage of #ACR24 is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by

      Dr. John Cush RheumNow

      9 months 3 weeks ago
      RheumNow’s expanded coverage of #ACR24 is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty
      The findings from ORAL Surveillance Study have been a dominant conversation at recent ACR Convergence, with the seminal findings and subsequent analyses a target of debate. Subsequent post-hoc analyses, follow-up studies, and claims data analyses have been used to further interpret the data, though a clear answer on safety is not certain. A study presented on Sunday reported on a new post-hoc analysis that provides new insights.
      A#2528
      Hes1/Piezo1 Pathway - role in osteocyte response to mechanical stimulus
      Yoda1 - Piezo1 agonist shown to help fx h

      Eric Dein ericdeinmd

      9 months 3 weeks ago
      A#2528 Hes1/Piezo1 Pathway - role in osteocyte response to mechanical stimulus Yoda1 - Piezo1 agonist shown to help fx healing in mice Piezo1 decrease in GIOP Basic sci research shows activation of pathway promotes mechanical stress response, decr GIOP #ACR24 @RheumNow
      Does adding a Clofutriben (HSD-1 inhibitor) w/ prednisone minimize the risks of steroid toxicities in #PMR patients?

      V

      Akhil Sood MD AkhilSoodMD

      9 months 3 weeks ago
      Does adding a Clofutriben (HSD-1 inhibitor) w/ prednisone minimize the risks of steroid toxicities in #PMR patients? VS placebo, PMR patients who received Clofutriben + Prednisone had substantial reductions in bone, lipid, and glycemic control parameters @RheumNow #ACR24
      Late-Breaking Abstract L07

      The CLASS Project introduces new global classification criteria for Anti-Synthetase Syndrom

      Antoni Chan MD (Prof) synovialjoints

      9 months 3 weeks ago
      Late-Breaking Abstract L07 The CLASS Project introduces new global classification criteria for Anti-Synthetase Syndrome (ASSD). Using the gold standard dataset, the key findings were: ✅ Definite ASSD: Sensitivity 94.3%, Specificity 99.7% ✅ Probable ASSD: Sensitivity 97.5%,… https://t.co/PtciIMTSsu https://t.co/jvJv2VNvHx
      The 🫀is muscle‼️

      💥From the maestro herself @JuliePaikMD underscores why cardiac involvement in myositis can't

      Caoilfhionn Connolly CaoilfhionnMD

      9 months 3 weeks ago
      The 🫀is muscle‼️ 💥From the maestro herself @JuliePaikMD underscores why cardiac involvement in myositis can't be overlooked. 🔥Crucial insights with major implications for patient care and outcomes #acr24 @RheumNow @HopkinsMedicine @jhrheumatology https://t.co/mw6BvkdF2w
      Does vasculitis flare with checkpoint inhibitors?

      @MDAndersonNews experience:
      17 stable pts
      4 pts flared - all able to

      David Liew drdavidliew

      9 months 3 weeks ago
      Does vasculitis flare with checkpoint inhibitors? @MDAndersonNews experience: 17 stable pts 4 pts flared - all able to be controlled (i.e. 13 didn't flare) Encouragement that stable vasculitis pts that need ICI should get them! #ACR24 ABST1986 @RheumNow https://t.co/jO4w3HWBMd
      A#2529
      Disparities in JIA
      Outcome documentation, best practices, access to at-risk pts, agency and access
      - outcomes ini

      Eric Dein ericdeinmd

      9 months 3 weeks ago
      A#2529 Disparities in JIA Outcome documentation, best practices, access to at-risk pts, agency and access - outcomes initially appeared to worsen - reflection of better documentation Improvement driven by pt global scores Disparity gap closed by 17% #ACR24 @RheumNow https://t.co/oOxs0jIvBK
      Risks for HCQ cardiotoxicity:
      👉>5 yrs use
      👉>5 mg/kg/d (cumulative dose >500,000 mg)
      👉CKD
      👉use NSA

      TheDaoIndex KDAO2011

      9 months 3 weeks ago
      Risks for HCQ cardiotoxicity: 👉>5 yrs use 👉>5 mg/kg/d (cumulative dose >500,000 mg) 👉CKD 👉use NSAID 👉preexisting heart dz 👉presence of ocular, derm, SkM toxicity - Dr M Garschik #ACR24 @rheumnow https://t.co/LFobgls4jm
      A#2530
      ANA reactive CD4 cells: elevated B cell help activation in SjD
      Unique autoreactive T cell cluster in SSc shows CD

      Eric Dein ericdeinmd

      9 months 3 weeks ago
      A#2530 ANA reactive CD4 cells: elevated B cell help activation in SjD Unique autoreactive T cell cluster in SSc shows CD4+ TRAIL+ IFN type I - unique to SSc Leads to decrease activation of APCs, decrease CD4 T effector fxn @RheumNow #ACR24 https://t.co/4JnA3SpVM8
      #2259💊 Anti-Obesity Meds in RA📊 152 RA patients on semaglutide/tirzepatide 🔑 Findings💥Significant ⬇?

      Caoilfhionn Connolly CaoilfhionnMD

      9 months 3 weeks ago

      #2259 💊 Anti-Obesity Meds in RA 📊 152 RA patients on semaglutide/tirzepatide 🔑 Findings 💥Significant ⬇️weight, BMI, ESR, CRP, lipids, pain VAS 💥Improved CVD risk ⛔ 15% GI side effects, 27% discontinued 🔎Study of impact on RA outcomes needed #ACR24 @RheumNow #ACRBest https://t.co/6LCTZl5173

      Cool study investigating differences in nailfold capillaroscopy, jives w/my clinical experience

      Compared to SLE, pts wi

      Mike Putman EBRheum

      9 months 3 weeks ago
      Cool study investigating differences in nailfold capillaroscopy, jives w/my clinical experience Compared to SLE, pts with DM 🔼nailfold changes, 🔼 loop dilation, 🔼hemorrhages #ACR24 @rheumnow Abstr#2404 https://t.co/8N7KNRZet8
      ×